HEXIM1 Inhibitors
The HEXIM1 inhibitors described here represent a class of compounds that indirectly modulate the activity of HEXIM1 through a variety of biochemical pathways. These inhibitors work by either targeting the transcription machinery components such as RNA polymerase II and CDK9, which are crucial for the synthesis of proteins that interact with or regulate HEXIM1, or by influencing the phosphorylation states and expression levels of proteins within these pathways. By doing so, they can alter the cellular equilibrium, resulting in increased inhibition by HEXIM1. These compounds share a common feature in that their primary modes of action are to disturb the normal function of P-TEFb, either by hindering the expression of its components or by promoting conditions that favor the inhibitory binding of HEXIM1 to P-TEFb.
The dynamic between P-TEFb and HEXIM1 is central to transcriptional regulation, and thus, modulation of this interaction is crucial for influencing HEXIM1 activity. The chemicals listed operate through direct inhibition of enzymes or by disrupting processes that are upstream of P-TEFb activity, resulting in an indirect but effective increase in HEXIM1's inhibitory action. This class of inhibitors does not directly target HEXIM1 but rather exerts their effect through a cascade of interactions that ultimately lead to the modulation of HEXIM1's role in transcriptional regulation. The intricate network of signaling and transcriptional pathways provides multiple points at which these inhibitors can exert their influence, making them a valuable tool for studying the complex biology of HEXIM1 regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB acts as an adenosine analog that inhibits RNA polymerase II, leading to reduced transcription elongation. This reduction in transcription can lead to lowered levels of cyclin T1, a key component of the positive transcription elongation factor b (P-TEFb) complex, to which HEXIM1 binds, resulting in its inhibition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDK9, a kinase component of P-TEFb, leading to suppression of RNA polymerase II-dependent transcription elongation. Reduced CDK9 activity can increase the association of HEXIM1 with the inactive P-TEFb complex, indirectly increasing HEXIM1 inhibition. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide inhibits transcription by affecting the XPB subunit of TFIIH and can lead to reduced transcriptional levels of P-TEFb components. This reduction may enhance the binding of HEXIM1 to P-TEFb, promoting HEXIM1's inhibitory role on P-TEFb. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid can induce the hyperphosphorylation of RNA polymerase II, a step potentially leading to transcriptional repression and decreased expression of P-TEFb components, which could enhance HEXIM1-mediated inhibition of P-TEFb. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Silvestrol, a eukaryotic translation initiation factor 4A (eIF4A) inhibitor, can downregulate RNA Polymerase II activity indirectly. This action could lead to decreased transcription of proteins involved in the HEXIM1 regulatory pathway, resulting in increased HEXIM1 inhibition. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA at transcription initiation complexes and prevents elongation by RNA polymerase. This binding could indirectly enhance HEXIM1's inhibitory effect on the P-TEFb complex by reducing the transcription of P-TEFb-related genes. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, leading to decreased transcription and potentially enhancing the pool of inactive P-TEFb complex bound to HEXIM1 due to lower levels of cyclin T1 and CDK9, the components of P-TEFb. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide inhibits eIF4A, impacting mRNA translation initiation. This inhibition can lead to reduced protein synthesis of factors that are part of or regulate the P-TEFb/HEXIM1 interaction, indirectly increasing HEXIM1's inhibitory potential. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin, a nucleoside analog, leads to premature termination of mRNA synthesis. This action can indirectly result in decreased levels of P-TEFb components, promoting the inhibition of P-TEFb by HEXIM1. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine Chloride is a potent inhibitor of Protein Kinase C (PKC). By inhibiting PKC, it can influence the phosphorylation states of proteins that interact with or regulate HEXIM1, potentially inhibiting HEXIM1’s activity. | ||||||